Postibrutinib relapse outcomes for patients with marginal zone lymphoma
Blood Adv
.
2023 Jan 10;7(1):88-91.
doi: 10.1182/bloodadvances.2022008634.
Authors
Narendranath Epperla
1
,
Qiuhong Zhao
1
,
Sayan Mullick Chowdhury
1
,
Lauren Shea
2
,
Tamara K Moyo
3
,
Nishitha Reddy
4
,
Julia Sheets
5
,
David M Weiner
6
,
Praveen Ramakrishnan Geethakumari
7
,
Malathi Kandarpa
8
,
Ximena Jordan Bruno
9
,
Colin Thomas
10
,
Michael C Churnetski
11
,
Andrew Hsu
12
,
Luke Zurbriggen
13
,
Xiao-Wei Cherie Tan
14
,
Kathryn Lindsey
15
,
Joseph Maakaron
16
,
Paolo F Caimi
17
,
Pallawi Torka
18
,
Celeste Bello
19
,
Sabarish Ayyappan
20
,
Timothy S Oh
21
,
Reem Karmali
21
,
Seo-Hyun Kim
22
,
Anna Kress
23
,
Shalin Kothari
23
,
Yazeed Sawalha
1
,
Beth Christian
1
,
Kevin A David
14
,
Irl Brian Greenwell
15
,
Murali Janakiram
16
,
Vaishalee P Kenkre
13
,
Adam J Olszewski
12
,
Jonathon B Cohen
11
,
Neil Palmisiano
10
,
Elvira Umyarova
9
,
Ryan A Wilcox
8
,
Farrukh T Awan
7
,
Juan Pablo Alderuccio
24
,
Stefan K Barta
6
,
Natalie S Grover
5
,
Nilanjan Ghosh
3
,
Nancy L Bartlett
2
,
Alex F Herrera
25
,
Geoffrey Shouse
25
Affiliations
1
Division of Hematology, The Ohio State University, Columbus, OH.
2
Division of Hematology, Washington University, St. Louis, MO.
3
Levine Cancer Center, Atrium Health, Charlotte, NC.
4
Vanderbilt University Medical Center, Nashville, TN.
5
Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC.
6
Division of Hematology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
7
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
8
Division of Hematology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
9
Division of Hematology and Oncology, University of Vermont, Burlington, VT.
10
Division of Hematology, Thomas Jefferson University, Philadelphia, PA.
11
Winship Cancer Institute, Emory University Medical Center, Atlanta, GA.
12
Division of Hematology, Brown University, Providence, RI.
13
Division of Hematology, University of Wisconsin, Madison, WI.
14
Cancer Institute of New Jersey, New Brunswick, NJ.
15
Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC.
16
Division of Hematology, University of Minnesota, Minneapolis, MN.
17
University Hospitals Seidman Cancer Center, Cleveland, OH.
18
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY.
19
Division of Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
20
Division of Hematology and Oncology, University of Iowa, Iowa City, IA.
21
Division of Hematology, Northwestern University, Chicago, IL.
22
Division of Hematology and Oncology, Rush University, Chicago, IL.
23
Division of Hematology, Yale University, New Haven, CT.
24
Division of Hematology, University of Miami, Miami, FL.
25
Division of Hematology, City of Hope, Duarte, CA.
PMID:
36269847
PMCID:
PMC9827027
DOI:
10.1182/bloodadvances.2022008634
No abstract available
MeSH terms
Chronic Disease
Disease-Free Survival
Humans
Lymphoma, B-Cell, Marginal Zone* / drug therapy
Lymphoma, B-Cell, Marginal Zone* / pathology
Neoplasm Recurrence, Local* / drug therapy
Grants and funding
UL1 TR001422/TR/NCATS NIH HHS/United States
UL1 TR001863/TR/NCATS NIH HHS/United States